CER-1236 for Acute Myeloid Leukemia and Related Conditions
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
- Age
- 18 – 85
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 18 (estimated)
- Sponsor
- CERo Therapeutics Holdings, Inc. · Industry
This trial is looking for patients with specific types of blood cancers. Participants will receive a treatment called CER-1236 and will be monitored for safety and effectiveness.
You may be able to join if
- I have been diagnosed with acute myeloid leukemia or myelodysplastic syndrome.
- I have 10% to 19% blasts in my blood.
- My lymphocyte count is above 0.3 x 10^9/L before treatment.
- I have an ECOG performance status of 0 or 1.
You may not be able to join if
- I have had a genetically modified cell product as treatment before.
- I do not have measurable leukemia in my bone marrow before starting treatment.
- I have an active autoimmune disease that required treatment in the last 2 years.
- I have a severe allergy to fludarabine, cyclophosphamide, or the study drug components.
- I have a medical or psychological issue that might affect my participation.
- I have a primary immunodeficiency disorder.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThis is a first in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (MRD) positive acute myeloid leukemia (AML), or TP53mut disease.
Loading trial locations…
No contact information available.